Skip to main content
. Author manuscript; available in PMC: 2017 Sep 7.
Published in final edited form as: J Am Acad Audiol. 2010 May;21(5):301–357. doi: 10.3766/jaaa.21.5.3

Figure 2.

Figure 2

Comparison of pure-tone thresholds measured on three separate visits in control (left) and cisplatin-treated subjects (right). Data are for SRO frequencies normalized to each subject’s highest audible frequency, F, defined during the baseline test. F-1 is ⅙ octave below F, F-2 is ⅙ octave below F-1, etc. Mean and standard error for thresholds at SRO frequencies are given.